title: Effect of zinc-carnosine chelate compound (Z-103), a novel antioxidant, on acute gastric mucosal injury induced by ischemia-reperfusion in rats.
abstract: The protective effect of a novel synthetic zinc-carnosine chelate compound, zinc N-(3-aminopropionyl)-L-histidine (Z-103), on the gastric mucosal injury induced by ischemia-reperfusion was studied in rats. Ischemia and reperfusion injury was produced on the rat stomach by applying a small clamp to the celiac artery for 30 min and by removal of the clamp for 30 min. The decrease in the gastric mucosal blood flow was not influenced by the treatment with Z-103. The increase in total area of the erosions on the stomach after ischemia-reperfusion and the increase in lipid peroxides in the gastric mucosa were significantly inhibited by the oral administration of Z-103. In addition, Z-103 inhibited lipid peroxidation of rat brain homogenate and liver microsome in vitro. These results suggest that the protective effect of Z-103 against the aggravation of gastric mucosal injury induced by ischemia-reperfusion may be due to its inhibitory effect on lipid peroxidation.
authors.affiliation: First Department of Medicine, Kyoto Prefectural University of Medicine, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Yoshikawa
authors.forename: Y
authors.initials: Y
authors.lastname: Naito
authors.forename: T
authors.initials: T
authors.lastname: Tanigawa
authors.forename: T
authors.initials: T
authors.lastname: Yoneta
authors.forename: M
authors.initials: M
authors.lastname: Yasuda
authors.forename: S
authors.initials: S
authors.lastname: Ueda
authors.forename: H
authors.initials: H
authors.lastname: Oyamada
authors.forename: M
authors.initials: M
authors.lastname: Kondo
mesh_terms: D000818:Animals; D000897:Anti-Ulcer Agents / Q000494:pharmacology*; D000975:Antioxidants / Q000494:pharmacology*; D001783:Blood Flow Velocity / Q000187:drug effects; D002336:Carnosine / Q000031:analogs & derivatives*; D002784:Cholesterol / Q000378:metabolism; D004151:Dipeptides / Q000494:pharmacology* / Q000627:therapeutic use; D005753:Gastric Mucosa / Q000098:blood supply / Q000378:metabolism / Q000473:pathology*; D015227:Lipid Peroxidation; D008297:Male; D009942:Organometallic Compounds / Q000494:pharmacology* / Q000627:therapeutic use; D010084:Oxidation-Reduction; D051381:Rats; D011919:Rats, Inbred Strains; D015427:Reperfusion Injury / Q000188:drug therapy* / Q000378:metabolism; D013858:Thiobarbiturates; D014810:Vitamin E / Q000378:metabolism; D015032:Zinc / Q000494:pharmacology*; D017967:Zinc Compounds
chemical_list: D000897:Anti-Ulcer Agents; D000975:Antioxidants; D004151:Dipeptides; D009942:Organometallic Compounds; D013858:Thiobarbiturates; D017967:Zinc Compounds; C061957:polaprezinc; D014810:Vitamin E; D002336:Carnosine; D002784:Cholesterol; D015032:Zinc; C029684:thiobarbituric acid